Introduction
============

CYP2D6 is a highly polymorphic drug metabolizing enzyme. To date 80 allelic variants including those described in this report and numerous subvariants have been defined by the cytochrome P450 nomenclature committee[1](#fn1){ref-type="fn"}. The collection of known alleles comprise variants encoding no, reduced, full, or ultrarapid CYP2D6 activity and give rise to corresponding poor (PM), intermediate (IM), extensive (EM), and ultrarapid (UM) metabolizer phenotypes. While the most frequent sequence variations are single nucleotide polymorphisms (SNPs) or small insertions/deletions, this gene locus also undergoes major recombination events creating alleles harboring large deletions, duplications, multiplications, conversions, and combinations thereof (Zanger et al., [@B14]; Gaedigk et al., [@B7]; Kramer et al., [@B10]; Gaedigk et al., [@B5]). The *CYP2D* gene locus contains direct repeat regions and highly homologous gene units which facilitate unequal crossing-over that can lead to allelic variants with large deletions and duplications (Hastings et al., [@B9]). Most prominent examples are the *CYP2D6*\**5* gene deletion, *CYP2D6*\**1xN*, \**2xN*, and \**4xN* gene duplications/multiplications and gene tandems such as *CYP2D6*\**36* + \*10 (the *CYP2D6*\**36* gene carries a *CYP2D7* conversion in exon 9). *CYP2D7/2D6* hybrid genes are recombination products that likely resulted from large deletion events that fused respective ends of both genes together and carry a T-insertion in exon 1 that causes premature termination. These hybrids are non-functional. We have recently described three alleles carrying non-functional hybrids upstream of intact *CYP2D6*\**1* and \**2* genes (*CYP2D6*\**76* + \*1, \*77 + \*2, and \**78* + \*2). Notably, these alleles presented as gene duplications when tested on certain platforms/assays and hence may be misclassified as *CYP2D6*\**1xN* and \**2xN*, if not fully characterized (Gaedigk et al., [@B5]). Kramer et al. ([@B10]) also have observed *CYP2D7/2D6* hybrid genes in single and tandem arrangements providing further evidence that hybrid genes may not be as rare as generally believed. A graphical overview is provided in Figure [1](#F1){ref-type="fig"}.

![**Overview of the *CYP2D7/2D6* hybrid genes**. *CYP2D6, CYP2D7*, and *CYP2D8* genes are shown in light gray, red, and dark gray boxes, respectively. The 600-bp repeat element immediately downstream of exon 9 is shown in blue. *CYP2D6* and *CYP2D7*-derived repetitive elements (REP) are in red and light gray; REP-DEL indicates a fused repeat element generated by a large deletion involving parts of those elements from both genes. PCR fragments generated are represented as lines and their sizes are given in kilobyte. Red and black endpoints denote primer specificity to *CYP2D6* and *CYP2D7*. **(A)** Graph represents the *CYP2D* reference locus. Areas affected by large deletions and implicated in *CYP2D7/2D6* hybrid formation and the *CYP2D6*\**5* gene deletion are as indicated. **(B)** Graphic display of the *CYP2D6*\**5* gene deletion allele. XL-PCR amplicons utilized for detection are shown. **(C)** Graphic display of *CYP2D7/2D6* hybrid genes and their detection by amplification of fragment H. Other depicted fragments are only amplified, if respective rearrangements are present in a sample. **(D)** Representation of an allele with a *CYP2D7* gene lacking the 1.6-kb spacer. This *CYP2D7* variant also supports formation of fragment H although the *CYP2D7/2D6* switch occurs in the downstream region.](fphar-01-00121-g001){#F1}

Testing of hybrid genes is rarely performed because their detection typically requires long-range PCR which is not amenable to automation (Figure [1](#F1){ref-type="fig"}). Hence, despite major *CYP2D6* genotyping efforts and the development of many commercially available platforms and test kits, hybrid genes remain elusive. In order to detect *CYP2D7/2D6* hybrid genes on a routine basis, we have modified our long-range (XL) PCR to not only generate the 6.6-kb long *CYP2D6*-specific amplicon which is subsequently used for genotyping, but also generate duplication-specific and hybrid-specific amplicons (Gaedigk et al., [@B5]) in a convenient triplex reaction. Prospective and retrospective application of this strategy resulted in the discovery of 12 subjects, which were hybrid-positive, in addition to the *CYP2D6*\**13* (EU098008) and *CYP2D6*\**66* (EU093102) index cases previously characterized. We also found an additional subject positive for the *CYP2D6*\**76* + \*2 tandem hybrid corroborating our previous finding (Gaedigk et al., [@B5]).

The goal of the present study was to characterize the hybrid genes within the *CYP2D* locus in these subjects in detail, assess their functionality using *in vivo* phenotype data with dextromethorphan as probe drug in a subset of individuals and describe strategies for their detection and analysis.

Materials and Methods
=====================

Subjects
--------

The subjects included in this analysis gave written informed consent to participate in studies involving genetic testing of the *CYP2D6* gene. Studies were approved by the Ethic Committees or Institutional Review Boards of the Institutions where the participants were enrolled (cohort 1: Children\'s Mercy Hospital, Kansas City, *n* = 490; cohort 2: University of Montreal, CHU Ste-Justine, *n* = 268; cohort 3: the University of the West Indies, *n* = 279; Morehouse School of Medicine, Atlanta, *n* = 272; or independent institutional review boards for samples obtained at Bassett Healthcare, Cooperstown, NY, *n* = 1 and Ordway Research Institute Drug Development Center, Albany, NY, *n* = 1). One sample was obtained through physician-requested diagnostic testing (Quest Diagnostics Nichols Institute). Genomic DNA was isolated from whole blood or saliva specimen collected in Oragene DNA sample collection disks (DNA Genotek, Kanata, ON, Canada) using column-based procedures and stored at 4ºC.

CYP2D6 activity determined by *in vivo* phenotyping
---------------------------------------------------

Urinary concentrations of dextromethorphan (DM) and its metabolite dextrorphan (DX) were determined by reversed-phase, high-performance liquid chromatography as described (Blake et al., [@B1]). Phenotype classification was made based on the urinary DM/DX ratio in 4-, 5-, and 12-h urine collections sampled in Kansas City and Atlanta, Trinidad and Cooperstown, respectively. UM, EM, IM, and PM categories are as defined by Gaedigk et al. ([@B8]).

Detection of hybrid genes by long-range PCR
-------------------------------------------

The simultaneous detection of the *CYP2D6* gene, hybrids and duplications were achieved by long-range (XL) PCR essentially as described in detail elsewhere (Gaedigk et al., [@B5]). Briefly, this XL-PCR triplex reaction produced a 6.6-kb-long amplicon from the *CYP2D6* gene, a 5-kb-long fragment (fragment H) (Figure [1](#F1){ref-type="fig"}) and a 3.5-kb-long fragment from gene duplications containing a *CYP2D6\[REP6\]* downstream sequence. Hybrid genes support formation of fragment H given that they are comprised of a *CYP2D7* sequence upstream of exon 1 and a *CYP2D6*-specific sequence downstream of *CYP2D6* exon 9. XL-PCR was performed at a final concentration of 5% DMSO with KAPA Long Range HotStart DNA Polymerase (KAPA Biosystems, Woburn, MA, USA) as prescribed by the manufacturer\'s protocol. Annealing temperature was 68ºC and extension times 1 min/1 kb. Reaction volumes were 8 μl containing 15--25 ng genomic DNA. Typically 1.5--3 μl of PCR product were analyzed by agarose gel electrophoresis. Primers and PCR amplicon lengths are given in (Gaedigk et al., [@B5]). Genotype analysis was performed on diluted triplex XL-PCR amplicons using PCR-RFLP-based assays as previously described (Gaedigk et al., [@B5]) to determine whether the hybrid genes carried *CYP2D6* or *2D7*-specific sequence variations in exons 1 and 9, respectively. For subsequent sequence analysis, fragment H was generated as sole amplicon under identical conditions. Genotype analysis for all other *CYP2D6* variants was either carried out by PCR-RFLP analysis as described in detail (Gaedigk et al., [@B8]) or using predesigned TaqMan assays (Applied Biosystems, Foster City, CA, USA). The latter were performed in 8-μl reaction volumes containing XL-PCR template diluted at least 1000-fold, 1× ProbeFast qPCR kit-ABI Prism ready mix (KAPA Biosystems, Woburn, MA, USA) and 1× TaqMan probes. Cycling parameters were as prescribed for the PCR kit and cycle number performed ranged from 35 to 45.

DNA sequence analysis
---------------------

For sequence analysis, fragment H was purified with the GenElute PCR Clean-Up Kit (Sigma, St Louis, MO, USA) and entirely sequenced using BigDye terminator v3.1 cycle sequencing chemistry and a 3730 capillary DNA analyzer (Applied Biosystems). Sequences deposited in GenBank (M33387, M33388, AY545216, EU098008, and EU093102 served as reference sequences for *CYP2D7*, *CYP2D6*, *CYP2D6*\**13* and \**16*, respectively. To determine the *CYP2D7* upstream sequence in more detail, a 5-kb-long amplicon was generated from five subjects (*CYP2D6*\**1/*\**5*; *CYP2D6*\**4/*\**4*; *CYP2D6*\**5/*\**5*; *CYP2D6*\**2/*\**41*, and *CYP2D6*\**1/*\**1* \[Coriell ID NA17111\]) with the following *CYP2D7*-specific primers: 5′- TCCGACCAGGCCTTTCTACCAC and 5′-CACCAGAAAGCTGACGACACGAGA. Exon 1 and the 276 bp of the upstream region were sequenced as described above.

Characterization of the *CYP2D* locus containing hybrid-duplication tandems
---------------------------------------------------------------------------

Long-range PCRs covering different regions of the *CYP2D* locus were performed with primers specific for *CYP2D6, CYP2D7*, and *CYP2D8*. XL-PCR was carried out as described previously (Daly et al., [@B2], Gaedigk et al., [@B5]). Figure [1](#F1){ref-type="fig"} provides a graphical display of the approximate region covered in the various reactions. Note that the 8-kb amplicon depicted in Figure [1](#F1){ref-type="fig"} corresponds to the XL-PCR first devised by Daly et al. ([@B2]) for the detection of *CYP2D6*\**13* and \**16*.

Genotyping assay detecting the *CYP2D7* exon 9 conversion and *CYP2D7\[REP6\]*
------------------------------------------------------------------------------

A 597-bp-long amplicon was amplified with a *CYP2D7*-specific forward primer directed at exon 9 (5′-AGCCACTCTCGTGTCGTCAGCTT) and a *CYP2D6*-specific reverse primer binding downstream of the gene (same binding site as the primer used to generate the 6.6-kb-long genotyping template; 5′-CGACTGAGCCCTGGGAGGTAGGTAG). A second pair of *CYP3A7* primers was added to the reaction that generated an 860-bp-long product (internal control) independently of the *CYP2D6* genotype. PCR was carried out in 8-μl reactions with RedJumpStart DNA polymerase (Sigma) and ∼15-ng genomic DNA. Cycling conditions comprised an initial denaturing step for 3 min at 94ºC that was followed by 42 cycles at 94ºC for 10 s, 68ºC for 10 s, and 72ºC for 30 s and a final hold at 10ºC. PCR fragments were subsequently resolved by agarose gel electrophoresis.

An RFLP-based assay discriminating *CYP2D6* from *CYP2D7* exon 9 sequences was carried out as following. A PCR product was amplified with primers encompassing exon 9 (forward primer 5′-GGCAAGGGTAACTGACATCTG; reverse primer 5′-CCTGGGAGGTAGGTAGCCCTG). PCR was carried out as described above, but an annealing temperature of 58ºC. The PCR products were subsequently incubated overnight at 37ºC with the restriction enzyme *Nco*I and then separated by agarose gel electrophoresis. *CYP2D6*-derived sequences were cut once (591 and 184 bp) while *CYP2D7*-derived sequences remained uncut (775 bp).

Results {#s1}
=======

Twelve subjects were identified by the triplex XL-PCR to carry *CYP2D7/2D6* hybrid gene structures (Table [1](#T1){ref-type="table"}).

###### 

**Summary of cases**.

  Subject \#   Origin^a^     Ethnicity^b^       Genotype                      Activity score   Predicted Phenotype^c^   DM/DX^d^
  ------------ ------------- ------------------ ----------------------------- ---------------- ------------------------ -------------------
  Index Case   Kansas City   C                  \**5/*\**66*                  0                PM                       1.511 (PM)
  Case 1       Quebec        C                  \**9/*\**66*                  0.5              IM                       n/a
  Case 2       Quebec        C                  \**5/*\**66*                  0                PM                       n/a
  Case 3                     C                  \**1/*\**66*                  1                slow-EM                  n/a
  Case 4       Cooperstown   C                  \**5/*\**66*^d^               0                PM                       2.17502 (PM)
  Case 5       Quebec        C                  \**6/*\**66\[variant\]*^f^    0                PM                       n/a
  Case 6       Albany        C                  \**6/*\**67*                  0                PM                       n/a
  Case 7       Coriell^e^    AA                 \**29/*\**80*                 0.5              IM                       n/a
  Case 8       Quebec        C                  \**2/*\**79*                  1                slow-EM                  n/a
  Case 9       Cooperstown   C                  \**4/*\**35B*                 1                slow-EM                  0.03783 (IM)
  Case 10      Kansas City   AA                 *2D7\[REP6\]* + \*1/\*17^g^   1.5              fast-EM                  n/a
  Case 11      Trinidad      Afro-Trinidadian   *2D7\[REP6\]*\**1/*\**2*^g^   2                fast-EM                  0.02102 (slow-EM)
  Case 12      Atlanta       AA                 *2D7\[REP6\]*\**1/*\**2*^g^   2                                         0.003 (fast-EM)
  Case 13      Trinidad      Indo-Trinidadian   \**4/*\**76* + \*1            1                                         0.0094 (fast-EM)

*^a^Origin denotes the city, province or state the participant was living in when enrolled; Coriell denotes that the DNA sample was obtained from the Coriell Institute. ^b^C, Caucasian; AA, African American. ^c^Predicted phenotypes are according to Gaedigk et al (Gaedigk et al., [@B8]). ^d^Observed phenotype using urinary ratio (DM/DX) as measure of CYP2D6 activity; corresponding phenotype group is shown in brackets. n/a, phenotype not available. ^e^Coriell ID NA17165. ^f^This CYP2D6*\**66A was partially sequenced (exon 7 switch region). ^g^The CYP2D6*\**1 allele carries a CYP2D7\[REP6\] (Figure [3](#F3){ref-type="fig"}, top panel)*.

The hybrid genes presented themselves by the presence of a 5-kb amplicon (fragment H) as shown in Figure [2](#F2){ref-type="fig"}A. The hybrid was confirmed by "solo" XL-PCR (Figure [2](#F2){ref-type="fig"}B) and its location immediately downstream of *CYP2D8* demonstrated by the generation of XL-PCR amplicons that span *CYP2D8* and different regions within the hybrid (the product covering *CYP2D8* through *CYP2D6* intron 6 is shown in Figure [2](#F2){ref-type="fig"}C). Also, as depicted in Figure [2](#F2){ref-type="fig"}C, none of the subjects was positive for a duplication event, i.e. produced the duplication-specific 3.5-kb-long XL-PCR product. Presence of other rearranged genes was excluded by a quantitative copy number assay (Ramamoorthy et al., [@B12]).

![**Long-range (XL) PCR products generated from hybrid genes and control samples**. Fragment designation corresponds to that provided in Figure [1](#F1){ref-type="fig"} and used throughout this manuscript. The genotypes of the cases are shown in Table [1](#T1){ref-type="table"}. PCR product lengths are given in kilobyte to the right, marker sizes on the left. All PCRs were carried out on genomic DNA. **(A)** Triplex XL-PCR showing the formation of fragment A (entire *CYP2D6* gene), fragment B (presence of gene duplication), and fragment H (indicating the presence of a *CYP2D7/2D6* hybrid gene). **(B)** Fragment H was generated by itself. Note that this fragment is weak in the triplex reaction in panel A for case 9, but unequivocally present when amplified "solo". **(C)** As expected from sequence data, cases 5, 6, and 7 generated a PCR product spanning *CYP2D8* to *CYP2D6* intron 6. *CYP2D6*\**66* (index case) and case 9 serve as negative controls (see Figure [3](#F3){ref-type="fig"} for hybrid details).](fphar-01-00121-g002){#F2}

Taken together, these results suggested that large deletion events removed parts of the 3′-region of *CYP2D7*, the intergenic region and parts of the 5′-region of *CYP2D6* to form *CYP2D7/2D6* hybrid genes as displayed in Figure [1](#F1){ref-type="fig"}.

Sequence analysis revealed that three of the 12 *CYP2D7/2D6* hybrid-positive cases (Table [1](#T1){ref-type="table"}) were identical and corresponded to the *CYP2D6*\**66* sequence previously described for our index case and deposited under accession number EU093102. This resequencing effort identified a G-insertion (TCAGG**G**AGGGAT) in exon 4 that introduced an additional frame shift and further corroborated the non-functional nature of the hybrid (the original sequence EU093102 was corrected accordingly). One subject (case 5) had a hybrid with an identical sequence in the *CYP2D7/2D6* switch region in exon 7 (Figure [3](#F3){ref-type="fig"}), but differed from *CYP2D6*\**66* in six positions, three of them being upstream of exon 1 (Figure [4](#F4){ref-type="fig"}). This allele is referred to here as *CYP2D6*\**66\[variant\]*.

![**Graphic overview of hybrid alleles and their *CYP2D7/2D6* switch region**. *CYP2D7* and *CYP2D6* portions are shown in red and gray boxes, respectively. The *CYP2D7* conversion in *CYP2D6*\**35\[variant\]* is shown as a red box upstream of exon 1. Switch regions are indicated in green. The red arrow notes a T-insertion in *CYP2D7* exon 1 relative to *CYP2D6*. The hybrid sequences were aligned with *CYP2D7* (M33387) and *CYP2D6* (M33388) reference sequences to approximate the switch region. For completion, the graph also shows previously reported *CYP2D6*\**76* + \*1, \*77 + \*2, and \**78* + \*2 tandem hybrids (Gaedigk et al., [@B5]) as well as the *CYP2D6*\**13* and \**16* alleles (no reference sequences deposited in GenBank; graphs based on descriptions in (Panserat et al., [@B11], Daly et al., [@B2]).](fphar-01-00121-g003){#F3}

![**Comparison of hybrid sequences upstream of exon 1 to *CYP2D6* and *CYP2D7* references**. *CYP2D6* sequences are highlighted in yellow, *CYP2D7* in green and sequence variation deviating from both in orange. Position numbers are given according to M33388 (first column, 1 = first nucleotide in M33388; second column, −1 = first nucleotide upstream of ATG start codon. The forward primer binding site for fragment H is shown in darker green in the M33387 reference sequence and limits the sequence information obtained from the hybrids (X denotes no sequence). A commonly used *CYP2D6*-specific primer binding site is shown in darker yellow in the M33388 reference sequence. For *CYP2D6*\**35B* ∼1.5 kb of upstream region was sequenced.](fphar-01-00121-g004){#F4}

Three subjects (cases 6, 7, and 8) had hybrid genes with a switch from *CYP2D7* to *CYP2D6* in exon 2, exon 3, and exon 5, respectively (Figure [3](#F3){ref-type="fig"}). These alleles were designated by the nomenclature committee as *CYP2D6*\**79*, \**80*, and \**67*; their corresponding GenBank accession numbers are HM641839, HM641840, and EU098009. Notably, all three variants carry a T-insertion in exon 1, a hallmark feature of *CYP2D7*, which does not support formation of functional protein due to premature translation termination.

In contrast, subject (case 9) was negative for the T-insertion and encoded an open reading frame that corresponded to *CYP2D6*\**35* and therefore the formation of active protein. However, the upstream region contained a 110-bp-long cassette (or inversion) that corresponded to *CYP2D7* and contained the primer binding site for the primer used to generate fragment H (Table [1](#T1){ref-type="table"}). When this subject was initially genotyped using a shorter XL-PCR template (Gaedigk et al., [@B6]), we determined a *CYP2D6*\**4/*\**4* genotype, which was discordant with the subject\'s phenotype. In contrast, analysis with our current procedure using a 6.6-kb-long template, two alleles were detected and the revised *CYP2D6*\**4/*\**35* genotype was consistent with the DM/DX ratio of 0.03783. While we could not explain this discrepancy at the time this subject was first genotyped over ten years ago, these findings are consistent with the discovery of the *CYP2D7* conversion cassette that prevents binding of the *CYP2D6*-specific primer we originally utilized (primer binding site is shown in Figure [4](#F4){ref-type="fig"}). To confirm the *CYP2D6* conversion, and determine additional sequence in the upstream region, the 6.6-kb-long XL-PCR product was sequenced in addition to fragment H. This allele was designated *CYP2D6*\**35B* and has been catalogued under accession number HM641838.

Sequence analysis of the hybrid genes amplified from cases 10, 11, and 12 revealed a *CYP2D7* gene lacking the 1.6 kb spacer sequence that is typically found downstream of *CYP2D7* between a 600 bp repeat region and REP7 (Figures [1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"} and Gaedigk et al., [@B5]). Due to the absence of the spacer sequence, the *CYP2D6*-specific reverse primer bound to this gene unit and supported amplification of a *CYP2D7/2D6* hybrid PCR product. In line with primer design (*CYP2D7*-specific forward and *CYP2D6*-specific reverse primer), the *CYP2D7\[REP6\]* gene was also detected by an assay we originally developed to screen genomic DNA for the presence of the exon 9 conversion in *CYP2D6* variants such as *CYP2D6*\**4N* and \**36*. As shown in Figure [5](#F5){ref-type="fig"}A, cases 10--12 produced a PCR product suggesting that the *CYP2D7/2D6* switch occurred downstream of exon 9. In contrast, these subjects were negative for the exon 9 conversion when the 6.6-kb-long *CYP2D6*-specific XL-PCR product was used as genotyping template excluding the possibility that the amplicon shown in Figure [5](#F5){ref-type="fig"}A is derived from an allele similar to *CYP2D6*\**4N* or \**36* (Figure [5](#F5){ref-type="fig"}B). The quantitative copy number assay (to be published elsewhere), revealed two copies for *CYP2D6* and *CYP2D7*, respectively indicating that no additional gene units are present. Taking all findings together we concluded that this "hybrid" is most likely derived from the *CYP2D7* gene possessing a *CYP2D6*-like downstream region, i.e., REP6 lacking the 1.6-kb-long spacer. Furthermore, because all three cases have a *CYP2D6*\**1* allele in common, *CYP2D7\[REP6\]* is most likely associated with *CYP2D6*\**1* as depicted in Figure [3](#F3){ref-type="fig"}.

![**Genotype analysis for *CYP2D7* exon 9 conversion and *CYP2D7\[REP6\]***. M, 100-bp ladder. Cases, positive, and negative control DNAs and their respective genotypes are as indicated. Selected marker bands are given in kilobyte to the left; PCR product and restriction fragment lengths are shown to the right in base pair. The top panel **(A)** shows a duplex assay performed on genomic DNA that detects the *CYP2D6* exon 9 conversion present in e.g., *CYP2D6*\**36* and alleles carrying a *CYP2D7\[REP6\]*. The forward primer is specific for *CYP2D7* exon 9 and the reverse primer for *CYP2D6* binding to the REP6 junction (see Figure [1](#F1){ref-type="fig"}). A second primer pair served as internal control (IC). Samples positive for *CYP2D6*\**36* or *CYP2D7\[REP6\]* produced a 597-bp long amplicon in addition to the 860-bp-long IC product. The bottom panel **(B)** shows a RFLP-based assay performed on the 6.6-kb long *CYP2D6*-specific genotyping template. Uncut PCR product (775 bp) is indicative of a *CYP2D7* exon 9-derived sequence on a *CYP2D6* background. The *CYP2D6*\**2/*\**36* control DNA sample is positive for *CYP2D7* exon 9 in both assays, while cases 10, 11 and 12 showed a *CYP2D6*-derived pattern in the RFLP assay (591 + 184 bp).](fphar-01-00121-g005){#F5}

Following are details for three cohorts for which a full set of experimental and demographic data were available to estimate hybrid allele frequencies: cohort 1 consisted of 490 subjects collected in the US who defined themselves as Caucasian (*n* = 329), African American (*n* = 83), Asian (*n* = 50), Hispanic (*n* = 10), Indian (*n* = 8), or did not fit into those categories (unknown, other and admixed, *n* = 10). Among those we discovered our *CYP2D6*\**66* index case (frequency of *CYP2D6*\**66* in the Caucasian subset was 0.1%) and one *CYP2D7\[REP6\]* carrier (*f* = 0.6% in the African American subset). Cohort 2 was a predominantly Caucasian cohort collected in Canada and the US and consisted of 268 subjects (*n* = 232 Caucasian, *n* = 13 African American, *n* = 9 Hispanic, *n* = 4 Asian, *n* = 10 admixed or of other ethnicity). Two *CYP2D6*\**66*, one \**66\[variant\]*, one novel \**79* hybrid and one \**77* + \*2 tandem hybrid allele were found in the Caucasians of this cohort (frequency of all single hybrids combined was 4/232 or 0.86%). A third cohort was composed of 174 Indo Trinidadians and 105 Afro Trinidadians among which only a single *CYP2D7\[REP6\]* was discovered in a subject with African ancestry (*f* = 0.5%). Notably an Indo Trinidadian subject revealed a *CYP2D6*\**76* + \*1 tandem hybrid, an allele so far observed in only one other subject who was African American (Gaedigk et al., [@B5]). To estimate the frequency for *CYP2D6*\**35B*, we screened an additional 28 carriers of *CYP2D6*\**35* from cohort 1. However, none were detected. Given a frequency of about 5% of *CYP2D6*\**35* in Caucasians (de Leon et al., [@B3]) the *CYP2D6*\**35B* subvariant appears to be rare (\<0.1%).

An alignment of the hybrid genes with *CYP2D6* and *CYP2D7* reference sequences revealed that the hybrid genes matched with the *CYP2D7* sequence given in ENSG00000205702 (Ensemble database), but not GenBank entry M33387 in the immediate upstream region of exon 1. Due to the differences between the two genes in this region, it is a preferred binding site for *CYP2D6*-specific gene amplification and frequently targeted by investigators. We resequenced *CYP2D7* of 10 alleles of selected subjects with *CYP2D6*\**1/*\**1*, \**1/*\**5*, \**4/*\**4*, \**5/*\**5*, and \**2/*\**41* genotypes to explore sequence variations within the upstream region of *CYP2D7*. As summarized in Figure [4](#F4){ref-type="fig"}, seven alleles corresponded to ENSG00000205702 and three exhibited CA at positions −203/−202, which was also observed in some of the hybrids. However, none matched M33387.

Discussion
==========

The *CYP2D6* gene locus has been extensively studied for allelic variation and ethnic differences. It is fair to state that this gene is amongst the most polymorphic drug metabolizing genes with 80 defined allelic variants, numerous recognized subvariants[1](#fn1){ref-type="fn"}, many variants with trivial names and some that remain unnamed. In addition to simple sequence variations such as SNPs, the locus is also known for major recombination events that created gene duplications, multiplications, conversions, and deletions (Steen et al., [@B13]; Kramer et al., [@B10]). Mechanisms that lead to changes in gene copy number and new combinations of exons between different genes via translocation, insertion or deletion have recently been reviewed by Hastings et al. ([@B9]). The *CYP2D* locus contains three highly homologous genes (*CYP2D6, 2D7*, and *2D8*) along repeat motifs constituting a perfect target for homologous recombination events. Such events are believed to be the mechanism by which *CYP2D7/2D6* hybrids were formed: the deletion of a 3′-portion of the *CYP2D7*, the intergenic region and a 5′-portion of *CYP2D6* results in a fused gene unit composed of *CYP2D7* and *CYP2D6*. The first hybrid genes described were *CYP2D6*\**13* and \**16* in which the switch occurred in intron 1 and somewhere between intron 7 and exon 8, respectively (Panserat et al., [@B11]; Daly et al., [@B2]) (Figure [3](#F3){ref-type="fig"}); these have recently also been detected by Kramer et al. ([@B10]). We now report additional hybrids switching to *CYP2D6* in exon 2, intron 2, and intron 5, a variant of *CYP2D6*\**66* and a *CYP2D7* variant with a *CYP2D6-like REP6* region mimicking a *CYP2D7/2D6* hybrid. The majority of subjects carrying hybrid genes or a hybrid in tandem arrangements (Gaedigk et al., [@B5]) are of Caucasian origin (Table [1](#T1){ref-type="table"}). To date we have identified only one subject of African ancestry with a "single" hybrid gene (case 7) and only two non-Caucasian subjects with a tandem hybrid (case 13, an Indo-Trinidadian and an African American described previously (Gaedigk et al., [@B5]), both having a *CYP2D6*\**76* + \*1). In contrast, all three subjects with a *CYP2D7\[REP6\]* are of African ancestry (cases 10, 11, and 12).

We estimate the combined frequency of "single" hybrid genes at 0.1--1% in Caucasians and \<0.1% in African Americans. This estimate is based on three cohorts which have systematically been interrogated for single as well as tandem hybrids. We have also screened an African American cohort for both single and tandem hybrids and only found a single individual with a hybrid, i.e., *CYP2D6*\**76* + \*1 (Gaedigk et al., [@B5]) further supporting a low frequency of such alleles in subjects of African ancestry. Before we started to routinely screen for such alleles we selected only samples presenting with rare homozygous genotypes such as *CYP2D6*\**5/*\**5* (index case) or \**6/*\**6* (case 6) for hybrid testing. The latter case, a Caucasian who was revised to *CYP2D6*\**6/*\**67*, was part of an ethnically mixed cohort of 285 subjects collected in Albany, NY. However, it remains unknown whether any other homozygous individuals of that sample cohort carry hybrids. Other cases were selected for a more complete characterization for a number of reasons. Case 3 for instance was tested with the AmpliChip P450 test in a diagnostic setting and revealed inconsistencies with the genotype of confirmed family members. Identification of a *CYP2D6*\**66* resolved these inconsistencies. Case 9 on the other hand initially revealed a genotype that was discordant with phenotype. This example illustrates how an unknown sequence variation can interfere with the genotyping procedure, i.e., prohibit primer binding, and thereby cause an incorrect genotype assignment. Unfortunately, a systematic re-evaluation of entire corresponding cohorts from which these cases were extracted was not feasible due to DNA availability, quality and/or expired patient consent.

We did not observe any single or tandem hybrids other than *CYP2D6*\**36* + \*10 in the 50 Asian subjects among our collection. The *CYP2D6*\**36* gene harboring the *CYP2D7* exon 9 conversion on an otherwise *CYP2D6* background in combination with a *CYP2D6*\**10* (also referred to as *CYP2D6*\**36* + \*10) is frequently detected when discriminated from the "single" *CYP2D6*\**10* allele (Ramamoorthy et al., [@B12]). While we are not aware of any other evidence that would suggest the presence of *CYP2D7/2D6* hybrids in Asians, larger population samples would need to be investigated.

In single and tandem configuration, hybrid genes with a *CYP2D7/2D6* switch beyond exon 1 are non-functional due to a T-insertion in this exon that leads to premature termination. A relatively simple strategy for hybrid detection and genotyping is to amplify a 5-kb-long PCR product and test for the presence of the T-insertion. We now routinely co-amplify this 5-kb-long amplicon (i.e., fragment H) along a duplication-specific fragment and a 6.6-kb-long product encompassing *CYP2D6* as described previously (Gaedigk et al., [@B5]). This triplex PCR not only provides information regarding the presence or absence of a hybrid and/or duplication, but can also be used as template to genotype for the T-insertion. An alternative strategy to detect hybrid genes in single and tandem configuration is to determine gene copy number in a quantitative manner. However, as discussed by Ramamoorthy et al. ([@B12]), the selection of assay, i.e. which part of the gene is interrogated, is crucial. We have established quantitative assays that probe in four different regions of the *CYP2D6* gene (exon 1, intron 5, intron 6, and exon 9) and two regions each of *CYP2D7* and *CYP2D8* (to be publishes elsewhere) and have applied these assays to the cases reported here. Results were consistent with all genotyping results obtained from genomic DNA and XL-PCR templates as well as additional XL-PCR amplifications spanning different regions of the *CYP2D* gene locus (Figures [1](#F1){ref-type="fig"}C,D and [2](#F2){ref-type="fig"}).

Of the four additional *CYP2D6*\**66* alleles we have resequenced, one differed in six positions suggesting that not all *CYP2D6*\**66* may have arisen from the same recombination event or that one variant accumulated additional SNPs. The *CYP2D6*\**66\[variant\]* matched with the apparently more common *CYP2D7* sequence corresponding to ENSG00000205702, while *CYP2D6*\**66* aligned with the minor *CYP2D7* allele (Figure [4](#F4){ref-type="fig"}).

Interestingly, one initially discordant subject (case 9) revealed a *CYP2D7* conversion in the upstream region of a *CYP2D6*\**35* (designated *CYP2D6*\**35B*) that first prevented its detection due to the lack of the *CYP2D6* primer binding site. Furthermore, this allele supported the formation of a PCR product described by Daly et al. ([@B2]) to detect *CYP2D6*\**16;* hence the initial *CYP2D6*\**4/*\**16* genotype assignment. When the genotyping template, however, was generated with a *CYP2D6* primer located further upstream, the *CYP2D6*\**35B* allele was detected. This case nicely illustrates how unknown sequence variability in a region that is frequently used as primer binding site can cause an incorrect genotype assignment that is discordant with phenotype.

Hybrid genes remain largely undetected using conventional genotyping strategies or platforms. However, depending on primer binding sites utilized and which part of a hybrid gene is derived from CYP*2D6* and *CYP2D7*, amplification may or may not proceed and thereby interfere with the genotype call. For example, if the *CYP2D6* portion is amplified, a wild-type call for a particular SNP would "mimic" the presence of a wild-type or *CYP2D6*\**1* allele. If no amplification takes place, the result reflects only that of the other allele leading to a homozygous genotype call. Thereby, "hidden" (undetected) hybrids may cause over-estimation of a subject\'s phenotype (e.g. *CYP2D6*\**1/*\**1* vs \**1/hybrid*) or may interfere with a genotyping results by producing unexplained/inconsistent genotyping results preventing unequivocal assignments. Indeed, a subset of the subjects described by Kramer et al. ([@B10]) were triaged for further characterization because of inconsistencies including data that could not be interpreted or homozygosity for rare alleles suggesting allele drop out or the presence of a hybrid gene. This strategy was also pursued by us to identify our first hybrid genes including our index case that was first published as *CYP2D6*\**5/*\**16* and later revised to *CYP2D6*\**5/*\**66* (Gaedigk et al., [@B6]; Gaedigk and Coetsee, [@B4]).

Phenotype information, i.e. urinary metabolic ratios of DM/DX was available for four subjects in addition to case 9 described in detail in the section ["Results"](#s1){ref-type="sec"} and the index case. For eight subjects phenotyping with DM was either not part of the study protocol or there was not sufficient urine available for analysis (case 10). Consistent with genotype, the index case and case 4 were phenotypic PMs with a DM/DX ratio \> 0.3. Without information for hybrid alleles, these two cases along case 2, 5, and 6 would have been assigned homozygous *null/null* genotypes (Table [1](#T1){ref-type="table"}), which would be consistent with the observed phenotype. The DM/DX ratios observed for cases 11--13 were also in general agreement. In contrast, *CYP2D6* activity towards DM would be overestimated for cases 1, 3, 7, and 8 because these subjects carry only one and not two copies of a functional or reduced activity allele. For example, case 1 would be misclassified as *CYP2D6*\**9/*\**9* with an activity score (AS) of 1.5 predicting an EM phenotype while the accurate *CYP2D6*\**9/*\**66* genotype with an AS of 0.5 predicted this individual to present as an intermediate metabolizer (Gaedigk et al., [@B8]).

*CYP2D7* genes lacking the 1.6-kb spacer sequence (referred to as *CYP2D7\[REP6\]*) and positioned upstream of a functional *CYP2D6* complicated the characterization and interpretation of true *CYP2D7/2D6* hybrid genes by also forming the 5-kb-long fragment H. It was distinguished from the other hybrid genes by being *CYP2D7* throughout exon 9 and being negative for any amplification with primers specific for *CYP2D7* and a sequence on the far 3′-end of the *CYP2D* locus as outlined in Figures [1](#F1){ref-type="fig"}B,C. In contrast, single hybrid genes support such amplicons. Furthermore, quantitative copy number determination including *CYP2D6* and *CYP2D7* supported the *CYP2D7\[REP6\]* structure shown in Figure [3](#F3){ref-type="fig"}.

In summary, our recent discoveries of recombination events creating hybrid genes in single and tandem rearrangements suggest that such events contribute significantly to the high degree of heterogeneity of the *CYP2D* gene locus. Furthermore, consistent discovery of additional cases with known and novel hybrids in different configurations and subjects of different ethnic and geographic origin demonstrates that such alleles are more common than initially believed. Their detection may improve the accuracy of genotype assignments and phenotype prediction. Assays amenable to automated and high(er) throughput testing, such as quantitative copy number detection, is a promising route to capture a variety of rearrangement event including the *CYP2D7/2D6* hybrids described in this report.
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